CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog in which the first 29 amino acids of growth hormone-releasing hormone are conjugated to a maleimidoproprionic acid (MPA) DAC technology linker that enables covalent binding to circulating serum albumin — extending its plasma half-life from minutes to approximately 6–8 days and allowing for sustained, continuous GH and IGF-1 elevation with infrequent dosing intervals in research models.
Unlike the no-DAC variant which mimics physiological pulsatile GH release, CJC-1295 with DAC produces a prolonged “GH bleed” — a sustained elevation of baseline GH and IGF-1 rather than discrete secretory pulses — making it the preferred research tool for studies requiring chronic GH axis stimulation, longitudinal IGF-1 tracking, and investigation of extended anabolic and metabolic effects of continuous GHRH receptor engagement.
Research has examined its applications in body composition, GH deficiency modeling, aging-related GH decline, and long-term anabolic signaling pathway characterization.
Specifications:
- Purity: ≥99% (HPLC verified)
- Form: Lyophilized powder
- Storage: −20°C
For Research Use Only.
Reviews
There are no reviews yet.